India's Sun Pharma aims to launch its obesity drug in five years, managing director says
India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...
BioSpace14h
Lilly Hops On Hot Molecular Glue Train With $1.2B+ Magnet Deal
The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and ...
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.
Modern Healthcare1d
GLP-1 compounding pharmacies sue FDA over shortage decision
Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its ...
The American Journal of Managed Care1d
Medicare Part D Spending Trends for Type 2 Diabetes Medications
New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...
Novavax reports large quarterly revenue declines, rethinks its strategic direction
Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a ...
AstraZeneca opens biomethane plant in UK to cut emissions
AstraZeneca has opened a plant to produce biogas from organic waste that will ensure by the end of this year all of its ...
clinicalpainadvisor.com1d
Novo Nordisk’s Wegovy, Ozempic No Longer in Short Supply, According to FDA
The Food and Drug Administration has determined that the shortage of Wegovy® (semaglutide) and Ozempic® (semaglutide) is resolved.
Prediction: Novo Nordisk Will Soar Over the Next 5 Years. Here's 1 Reason Why.
After quite a crushing bull stampede in 2024, the stock price of weight loss drug star Novo Nordisk (NYSE: NVO) has come down ...
Promising Growth Stocks To Follow Now – February 25th
Novo Nordisk A/S, Apollo Global Management, BlackRock, Blackstone, Prologis, Welltower, and Ventas are the seven Growth ...
NJBIZ2d
Drug compounders sue FDA over Novo Nordisk’s Ozempic, Wegovy (updated)
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
MM&M2d
What did Big Pharma CEOs get paid in 2024?
Despite the continued success of GLP-1 drugs Ozempic and Wegovy, Novo Nordisk CEO Lars Fruergaard Jørgensen took a slight pay cut in 2024. He received 57.1 million Danish kroner (DKK) – $8 million – ...